Today, Alvotech and Advanz Pharma jointly announced that the European Commission has granted marketing authorizations across the European Economic Area (EEA) for Gobivaz®, a biosimilar to Simponi® (golimumab), marking a significant milestone for biosimilar access and specialty pharmaceutical operations in Europe. The approval encompasses multiple formats of Gobivaz®, including 50 mg/0.5 mL and 100mg/mL dosages offered in both pre-filled syringes with passive needle safety guards and autoinjector forms, covering a wide range of indications. These include adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, ulcerative colitis, and children aged two years and older with juvenile idiopathic arthritis, also in combination with methotrexate.

The European Commission approval is based on comprehensive analytical and clinical evidence, including confirmatory studies comparing efficacy, safety, and immunogenicity of Gobivaz® (golimumab, AVT05) to Simponi® in patients with moderate to severe rheumatoid arthritis. Notably, positive top-line results from these studies played a pivotal role in demonstrating the biosimilar’s equivalence to the reference product. This regulatory achievement follows the earlier positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (EMA CHMP), solidifying Gobivaz®’s regulatory pathway in Europe and reinforcing Advanz Pharma’s commitment to specialty and hospital medicine access throughout the region.

Under the partnership, Alvotech is responsible for the development and commercial supply of Gobivaz®, while Advanz Pharma holds the exclusive registration and commercialization rights in the EEA and UK. This marks the second biosimilar approved within the strategic partnership of the two companies, further establishing their market presence and ability to deliver dependable supply chains for high-quality biosimilars. Both companies have emphasized their collaborative mission to increase market access and economic value for European healthcare systems facing growing pressures of biologic medicine costs and supply complexity.

Gobivaz® represents a significant advancement in the European biosimilars sector—one that aligns with the region’s evolving legislative and regulatory compliance requirements for biologics and biosimilars. Through enabling higher treatment volumes and improved cost efficiencies, it directly impacts procurement professionals and regulatory teams across specialty hospitals, while also presenting new strategic possibilities for contract research organizations (CROs) and contract manufacturing organizations (CMOs) involved in supply, packaging, and direct distribution. The approval is especially noteworthy as Gobivaz® is the first biosimilar to Simponi® to gain such comprehensive regional authorization, setting a precedent for monoclonal antibody biosimilar market entry and supporting long-term pharmaceutical purchasing strategies.

Alvotech’s role as a global biotech partner and Advanz Pharma’s expertise in commercialization—spanning more than 90 countries with direct presence in over 20—facilitate robust distribution and compliance coverage. Their integrated approach addresses key challenges facing Europe’s pharmaceutical quality assurance professionals and supply chain managers, such as maintaining consistency in product quality standards, regulatory harmonization, and continuous supply in the midst of evolving clinical guidelines and competitive industry dynamics.

Biosimilars like Gobivaz® are central to Europe’s ongoing efforts to achieve drug cost containment, broaden patient access, and ensure sustainable health system budgets. The market entry of Gobivaz®—supported by a totality of clinical and analytical data—strengthens the business case for increased investment in biosimilar development, contract drug discovery, and downstream manufacturing operations across the region. Strategic partnerships like that of Alvotech and Advanz Pharma are increasingly critical in navigating the regulatory landscape, technological advancements in antibody therapeutics, and the complexities of commercialization in diverse European markets.

Moving forward, both companies have signaled commitments to further broadening their biosimilar pipeline and expanding access through advanced supply chain innovations and partnerships. The approval of Gobivaz® exemplifies the confluence of regulatory achievement, market strategy, biotechnology innovation, and operational excellence needed to drive growth in the European pharmaceutical sector.